Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06040541 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 30, 2026 to Dec 31, 2026v9
  2. Enrollment target: 444 to 604 Study sites revised (17)v8 Show 1 more changeShow less
    • Study sites revised (17)

    See this version in full on ClinicalTrials.gov ↗

  3. Site details revised at 1 of 17 sitesv7
  4. Re-verified, no change to tracked fieldsv6
  5. Site details revised at 1 of 17 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Enrollment target: 290 to 444 Primary completion date: Aug 30, 2025 to Apr 30, 2026 · Study sites: 7 to 17 · Completion date: Jul 31, 2026 to Apr 30, 2027 · 6 morev4 Show 9 more changesShow less
    • Primary completion date: Aug 30, 2025 to Apr 30, 2026
    • Study sites: 7 to 17
    • Completion date: Jul 31, 2026 to Apr 30, 2027
    • Interventions: RMC-9805 (Drug) to RMC-6236 (Drug), RMC-9805 (Drug)
    • Eligibility criteria shortened, about 6 words
    • Secondary endpoints revised (10)
    • Study description expanded, about 17 words
    • Study arms: 1 to 2
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 5 to 7v3
  3. Study sites: 2 to 5v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Revolution Medicines, Inc.
16 trials monitored
See 1 trial at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
and 1 more disease
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Trial Details
NCT Number NCT06040541
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment 604 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov